Duchenne muscular dystrophy (DMD) is a progressive wasting disease of skeletal and cardiac muscles, representing one of the most common recessive fatal inherited genetic diseases with 1:3500–1:5000 in yearly incidence. It is caused by mutations in the DMD gene that encodes the membrane-associated dystrophin protein. Over the years, many have been the approaches to management of DMD, but despite all efforts, no effective treatment has yet been discovered. Hope for the development of potential therapeutics has followed the recent advances in genome editing and gene therapy. This review gives an overview to DMD and summarises current lines of evidence with regard to treatment and disease management alongside the appropriate considerations.
- Duchenne Muscular dystrophy
- gene therapy
- genome editing
- skeletal muscle
Statistics from Altmetric.com
Contributor VC and AM developed the idea and layout of this review. VC wrote the first draft of the manuscript. VC and AM revised and edited the final draft of the manuscript and approved the final text for submission.
Funding AM’s work has been supported by the European Union and The Royal Society (grants: FP7-PEOPLE-PCIG14-GA-2013-631440, 2014-2018 and RG140470 Research Grant, 2015-2016) and the Hull York Medical School. VC was funded by the INSPIRE project through Wellcome Trust at the Hull York Medical School.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.